 Home > Active Ingredient News > Antitumor Therapy > Ther Adv Med Oncol: In patients with advanced pancreatic cancer who failed FOLFIRINOX treatment, GnP (gemcitabine + albumin-bound paclitaxel) is a feasible treatment measure

Ther Adv Med Oncol: In patients with advanced pancreatic cancer who failed FOLFIRINOX treatment, GnP (gemcitabine + albumin-bound paclitaxel) is a feasible treatment measure

 Last Update: 2022-01-08
 Source: Internet
 Author: User

Tags

medical grade sunscreen

larin 1 20

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

FOLFIRINOX and GnP (gemcitabine + albumin-bound paclitaxel) can be selected as the first-line treatment for advanced pancreatic cancer patients with better physical fitness scores
.

Phase III clinical studies of PRODIGE and MPACT found that the median OS of first-line treatment with FOLFIRINOX and GnP was 11.

FOLFIRINOX and GnP (gemcitabine + albumin-bound paclitaxel) can be selected as the first-line treatment for advanced pancreatic cancer patients with better physical fitness scores

A total of 40 patients were enrolled from May 3, 2018 to December 17, 2019
.

The median age of the patients was 62 years (interquartile range (IQR), 41-82)

A total of 40 patients were enrolled from May 3, 2018 to December 17, 2019

The median progression-free survival was 5.

Overall population PFS and OS

The best overall response included partial response in 6 cases (15.
0%), stable disease in 29 cases (72.
5%), disease progression in 5 cases (12.
5%), and objective response rate (ORR) of 15.
0% (95% CI, 5.
7-29.
8) , DCR is 87.
5% (73.
2-95.
8)
.

The best overall response included partial response in 6 cases (15.

Efficacy evaluation

Among the 35 metastatic patients, the median PFS and OS were 5.
8 months (95% CI, 4.
3 8.
7) and 10.
3 months (95% CI, 7.
9 13.
3), respectively
.

The best overall response included partial response in 6 cases (17.

Among the 35 metastatic patients, the median PFS and OS were 5.

PFS and OS in metastatic patients

Twenty-one patients (52.
5%) received third-line treatment after failing second-line GnP
.

Eighteen patients (45.

Twenty-one patients (52.

Twenty-five patients (62.

AEs

In summary, studies have shown that in patients with advanced pancreatic cancer who failed FOLFIRINOX treatment, GnP (gemcitabine + albumin-bound paclitaxel) showed good anti-tumor efficacy and acceptable toxicity
.
Studies have shown that in patients with advanced pancreatic cancer who have failed FOLFIRINOX treatment, GnP (gemcitabine + albumin-bound paclitaxel) shows good anti-tumor efficacy and acceptable toxicity
.
Studies have shown that in patients with advanced pancreatic cancer who have failed FOLFIRINOX treatment, GnP (gemcitabine + albumin-bound paclitaxel) shows good anti-tumor efficacy and acceptable toxicity
.

Original source:

Huh G, Lee HS, Choi JH, Lee SH, Paik WH, Ryu JK, Kim YT, Bang S, Lee ES.
Gemcitabine plus Nab-paclitaxel as a second-line treatment following FOLFIRINOX failure in advanced pancreatic cancer: a multicenter, single -arm, open-label, phase 2 trial.
Ther Adv Med Oncol.
2021 Nov 10;13:17588359211056179.
doi: 10.
1177/17588359211056179.
PMID: 34790261; PMCID: PMC8591648.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.